Jefferies Financial Group Inc. JEF
NYSE · United States · Finance
$45.73-0.79 (-1.70%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Jefferies Financial Group (NYSE:JEF) reported Q3 earnings that came in ahead of market expectations. The group posted record investment banking revenue for the quarter, supported by strong equity underwriting activity. Fixed income trading revenue weakened sharply on a year-on-year basis, even as other divisions reported stronger results. The combination of a Q3 earnings beat, record investment banking revenue and softer fixed income trading is consistent with trends our broader work has...
Investing.com -- Jefferies identified three biotechnology stocks that appear undervalued with strong commercial prospects despite a challenging macro environment. The firm noted that rising interest rates are pressuring small and mid-cap biotech companies, potentially shifting investor focus toward late-stage and commercial-stage names. All three of the highlighted stocks are positioned to launch products with significant peak sales potential.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
JEF's record Q3 IB revenues point to stronger M&A and equity issuance, but major banks may see mixed results.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.